EURETINA 2020 Virtual – Prize Papers

Programme ScheduleProgramme Overview
EURETINA Sessions Keynotes Symposia Instructional Courses Free Paper Abstracts Poster Abstracts Prize Papers Load Favourites

Please note that all times are in Central European Summer Time (CEST)

Programme Filter
timer Loading ... please wait
Count: 6 Abstracts

Abstract Channel
Programme Breakdown
Count: 6 Abstracts

Abstract Channel
Programme Breakdown
Count: 6 Abstracts

Abstract Channel
Programme Breakdown
Count: 8 Abstracts

Abstract Channel
Programme Breakdown
Count: 6 Abstracts

Abstract Channel
Programme Breakdown
Count: 6 Abstracts

Abstract Channel
Programme Breakdown
Count: 6 Abstracts

Abstract Channel
Programme Breakdown
close
timer Loading ... please wait

EURETINA 2020 Virtual

Frank Holz

Prof. Frank G. Holz, FEBO, FARVO

University Eye Hospital Bonn
EURETINA President

Dear Colleagues,

On behalf of myself and the board of EURETINA, I would like to extend my sincere gratitude to you for supporting EURETINA 2020 Virtual by joining us for our first online meeting on 2 – 4 October. With over 8,000 registrations to the event, we are delighted with the tremendous success of the virtual format.

We hope that you enjoyed the event from the comfort of your home and please be reminded that you can watch all your favourite and missed sessions through EURETINA playback on the virtual platform over the next three months.

I would like to take this opportunity to remind you that through the course of this year, I have initiated together with the board of EURETINA a strategic Roadmap 2025 to outline the priorities of the Society moving forward. You can find a copy of the road map in your virtual briefcase on the virtual platform and website.

The virtual Congress included a virtual Exhibition, as well as virtual Networking Lounges and the usual programme of industry sponsored Satellite Symposia. We are most grateful to our loyal sponsors for their support in this new endeavour and were glad to be able to still have the opportunity to engage directly with them during the annual meeting.

We look forward to seeing you again next year at what we hope will be a live congress. However, this year has taught us that the congress can be successful no matter what the format due to the commitment of its members and supporters.

With very best wishes,

Prof. Frank G. Holz, FEBO, FARVO
President, EURETINA

Registration Information

Virtual Meeting Login

Opens 1200pm CEST Thursday 1 October

Already registered for the Virtual Congress 2020?

Platform for both exhibitors & delegates

Do you have a VAT number? If so, please contact registration@euretina.org for information on how to register. Please also contact us if you are a registered business located outside of the EU.

If you are an EURETINA Member or have submitted an abstract, you may already have an account.

If you do not know the login details for this account, please click on the ‘Forgot password’ link on the registration page and they will be sent to you. Alternatively, contact the Registration Department.

Prices are in Euro & listed without VAT
VAT is charged at 20%
EARLY FEE
5 Aug – 25 Sept
LATE FEE
26 Sept – 4 Oct
EURETINA Member5065
Non – Member95110
Ophthalmic Nurse / Technician*5065

*Documentation such as a work ID or verification letter from your hospital is required and must be uploaded during the registration process for approval.

CME credits will only be awarded to those who attended the live meeting from 2-4 October 2020

Additional Info Categories Groups Cancellations

Keynote Lectures – EURETINA 2020 Virtual

Richard Spaide USA speakerfeature EURETINA Lecture Richard Spaide USA
Marta S. FigueroaKreissig LectureMarta S. FigueroaSPAIN
Stanislao RizzoGisbert Richard Lecture Stanislao RizzoITALY

src

Safety Review Committee (SRC) Report

Post-marketing reports have highlighted the occurrence of intraocular inflammation (IOI) in association with retinal vasculitis and retinal vascular occlusion with brolucizumab, which differs from the common experience with other approved anti-VEGF agents.

A Safety Review Committee (SRC) consisting of clinical trial, imaging, and uveitis experts as well as Data Monitoring Committee members was established by Novartis to independently review these post-marketing cases.

View Report

Sign up to EURETINA


Loading please wait